SHUKRAPHAR — Peer Comparison
How the peer fair value is calculated and which companies were used as benchmarks.
Sign in to see this
Sign inPeer selection
Peers are selected from the same Healthcare industry. 8 companies were matched as valid comparables.
Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.
Peer comparison table
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
SHUKRAPHAR SHUKRAPHAR · you | ₹2,651 Cr | 73.5× | 49.0× | — | 66.4% | 0.6% | — |
| Sector median | — | 45.1× | 6.7× | 25.1× | 12.7% | 6.8% | 14.5% |
| Park Medi World Limited PARKHOSPS | ₹12,549 Cr | 40.9× | 6.0× | 27.2× | 12.8% | 15.4% | 10.2% |
| Akums Drugs and Pharmaceuticals Limited AKUMS | ₹12,161 Cr | 45.1× | 3.5× | 20.9× | 7.7% | 5.9% | 6.0% |
| Thyrocare Technologies Limited THYROCARE | ₹9,929 Cr | 60.9× | 20.7× | — | 34.0% | 0.2% | — |
| Jupiter Life Line Hospitals Limited JLHL | ₹9,880 Cr | 53.4× | 6.7× | 29.1× | 12.6% | 12.9% | 18.9% |
| Procter & Gamble Health Limited PGHL | ₹9,850 Cr | 27.6× | 16.1× | — | 58.5% | 0.3% | — |
| Healthcare Global Enterprises Limited HCG | ₹8,780 Cr | 638.1× | 6.6× | 21.3× | 1.0% | 0.5% | 14.5% |
| Sanofi India Limited SANOFI | ₹7,249 Cr | 45.1× | 28.2× | 23.0× | 62.5% | 27.3% | — |
| Nephrocare Health Services Limited NEPHROPLUS | ₹6,944 Cr | 83.4× | 6.1× | 28.8× | 6.9% | 7.7% | 31.7% |
SHUKRAPHAR trades at a premium to peers (P/E 73.5× vs median 45.1×), but its higher ROE of 66.4% (sector 12.7%) justifies much of that premium — quality rarely comes cheap.
Sign in to see this
Sign inWhy median? Why these weights?
Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.
Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.
Limitations of peer comparison
Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.
The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.